Stock Taper Adjusted Net Investment Income: $0.32 per share, fully covering the dividend of $0.32 paid on March 31.
Dividend Declaration: A reduced dividend of $0.25 per share was announced for Q2 2026, payable on June 30.
Book Value: $10.92 per share as of March 31, with a pro forma value of $10.95 post-buybacks.
Total Investment Income: $69 million, an 11% decrease from the prior quarter.
Net Expenses: $37 million, down 18% due to a voluntary incentive fee waiver of $6.1 million.
Nonaccruals: Increased to 2.6% of fair value, with specific concerns around Affordable Care and Convey.
Debt-to-Equity Ratio: 1.08:1, within the target range of 1.0x to 1.25x.
Asset Sale: Successfully sold $470 million of illiquid positions at 94% of book value, enhancing liquidity and enabling a strategic pivot.
Stock Buybacks: Approximately $57 million completed by March 31, with an additional $50 million authorized, totaling $80 million available for future buybacks.
Portfolio Composition: 91% of the portfolio rated green, with a focus on defensive sectors and strategic investments in healthcare and IT.
Market Positioning: Increased focus on higher-yielding loans due to wider spreads in the market, with an average yield of 11.1% for the portfolio.
Optimistic on Earnings: The company expects the reduced dividend to be more than covered by core business earnings.
Market Conditions: Anticipates continued opportunities for investment in high-quality assets at attractive valuations.
M&A Activity: Cautiously optimistic about the M&A market picking up, with plans to monetize equity positions in the near to medium term.
Increased Nonaccruals: The rise in nonaccruals, particularly related to Affordable Care, raises concerns about credit quality.
Market Volatility: Broader market bearishness impacted book value, with a significant portion of NAV decline attributed to market movements rather than specific loan performance.
Sector Scrutiny: Increased media scrutiny on private credit and software loans, with concerns about systemic credit stress, although NMFC does not see evidence of widespread issues.
Nonaccruals Clarification: Management clarified that the increase in nonaccruals was primarily due to two specific positions and expressed optimism about their recovery.
Yield Composition: The reported yield of 15.5% for new fundings was attributed to a combination of discounted purchases and market conditions.
Leverage Strategy: NMFC aims to maintain a leverage ratio within the 1x to 1.25x range, balancing between buybacks and new investments.
Market Spread Dynamics: Spreads have widened, providing opportunities for better pricing on new loans, with an emphasis on maintaining a conservative risk profile. Overall, NMFC's Q1 2026 results reflect a strategic repositioning following an asset sale, with a focus on maintaining financial stability while navigating market challenges. The company remains optimistic about future earnings potential despite some credit quality concerns.
SOURCE: Q1 2026 EARNINGS CALL TRANSCRIPT